Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies

References

• Kishor Ganti A, Kessinger A. Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cáncer. Cancer Treat Rev 2011;37:440-3
   Google Scholar
• Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003;327:794-8
   PubMed Web of Science ®Google Scholar
• Youssef KK, Van Keymeulen A, Lapouge G. Identification of the cell linage at the origin of basal cell carcinoma. Nat Cell Biol 2010;12:299-305
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Holm EA. Nonmelanoma skin cancer in organ transplant patients. Trasplantation 2003;75:253-7
   PubMedGoogle Scholar
• Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer 2011;2011:650258
   Google Scholar
• Michaëlsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol 1981;61:497-503
   PubMed Web of Science ®Google Scholar
• van Steensel MA, Jaspers NG, Steijlen PM. A case of Rombo syndrome. Br J Dermatol 2001;144:1215-18
   PubMed Web of Science ®Google Scholar
• Ashinoff R, Jacobson M, Belsito DV. Rombo syndrome: a second case report and review. J Am Acad Dermatol 1993;28:1011-14
   PubMed Web of Science ®Google Scholar
• Bazex A, Dupré A, Christol B. Génodermatose complexe de type indéterminé associant une hypotrichose, un état atrophodermique généralisé et des dégénérescences cutanées multiples (épithéliomas-basocellulaires). Bull Soc Fr Dermatol Syphiligr 1964;71:206
   Google Scholar
• Plosila M, Kiistala R, Niemi KM. The Bazex syndrome: follicular atrophoderma with multiple basal cell carcinomas, hypotrichosis and hypohidrosis. Clin Exp Dermatol 1981;6:31-41
   Google Scholar
• Kidd A, Carson L, Gregory DW, et al. A Scottish family with Bazex-Dupré-Christol syndrome: follicular atrophoderma, congenital hypotrichosis, and basal cell carcinoma. J Med Genet 1996;33:493-7
   Google Scholar
• Castori M, Castiglia D, Passarelli F, Paradisi M. Bazex-Dupré-Christol syndrome: an ectodermal dysplasia with skin appendage neoplasms. Eur J Med Genet 2009;52:250-5
   PubMedGoogle Scholar
• Abuzahra F, Parren L, Frank J. Multiple familial and pigmented basal cell carcinomas in early childhood – Bazex-Dupré-Christol syndrome. J Eur Acad Dermatol Venereol 2012;26(1):117-21
   Google Scholar
• Ponti G, Losi L, Di Gregorio C, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 2005;103:1018-25
   Google Scholar
• Draznin M, Robles DT, Nguyen V, Berg D. An unusual case of Bloom syndrome presenting with basal cell carcinoma. Dermatol Surg 2009;35:131-4
   Google Scholar
• Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 2001;102:11-17
   PubMed Web of Science ®Google Scholar
• Howell SM, Bray DW. Amelanotic melanoma in a patient with Rothmund-Thomson syndrome. Arch Dermatol 2008;3:416-17
   Google Scholar
• Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 2003;95:669-74
   PubMed Web of Science ®Google Scholar
• Jones EA, Sajid MI, Shenton A, Evans DG. Basal cell carcinomas in Gorlin syndrome: a review of 202 patients. J Skin Cancer 2011;2011:217378
   PubMedGoogle Scholar
• Castori M, Morrone A, Kanitakis J, Grammatico P. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol 2012;22:299-309
   Google Scholar
• Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma:presentation, pathogenesis and management. Cancer Metastasis Rev 2004;23:389-402
   PubMed Web of Science ®Google Scholar
• Mosterd K, Krekels GA, Nieman FH. Surgical excision versus Mohs micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomized controlled trial with 5 years follow up. Lancet Oncol 2008;9:1149-56
   PubMed Web of Science ®Google Scholar
• Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer 1994;73:328-35
   PubMed Web of Science ®Google Scholar
• Wermuth HW, Fajardo LF. Metastatic basal cell carcinoma. A review. Arch Pathol 1970;90:458-62
   PubMedGoogle Scholar
• Christian MM, Murphy CM, Wagner Jr RF. Metastatic basal cell carcinoma presenting as unilateral lymphedema. Dermatol Surg 1998;24:1151-3
   Google Scholar
• Woods RL, Stewart JF. Metastatic basal cell carcinoma: report of a case responding to chemotherapy. Postgrad Med J 1980;56:272-3
   PubMed Web of Science ®Google Scholar
• Salem P, Hall SW, Benjamin RS, et al. Clinical phase I–II study of cis-dichloro-diammineplatinum(II) given by continuous lv infusion. Cancer Treat Rep 1978;62:1553-5
   PubMedGoogle Scholar
• Wieman TJ, Shively EH, Woodcock TM. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer 1983;52:1583-5
   PubMed Web of Science ®Google Scholar
• Guthrie TH, Jr McElveen LJ, et al. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 1985;55:1629-32
   PubMed Web of Science ®Google Scholar
• Guthrie Jr TH, Porubsky ES, Luxenberg MN, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990;8:342-6
   Google Scholar
• Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma – a review of the literature. Acta Oncol 1996;35:677-82
   PubMed Web of Science ®Google Scholar
• Jefford M, Kiffer JD, Somers G, et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg 2004;74:704-5
   PubMed Web of Science ®Google Scholar
• Krahn G, Leiter U, Kaskel P, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001;37:251-9
   PubMed Web of Science ®Google Scholar
• Müller H, Eisendle K, Gastl G, et al. Palliative therapy of giant basal cell carcinoma with the monoclonal anti-epidermal growth factor receptor antibody cetuximab. Br J Dermatol 2008;158:1386-8
   PubMedGoogle Scholar
• Cirrone F, Harris C. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther 2012;34:2039-50
   PubMedGoogle Scholar
• Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010;28:5321-6
   PubMed Web of Science ®Google Scholar
• Gupta S, Takebe N, Lorusso P. Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol 2010;2:237-50
   PubMedGoogle Scholar
• Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen mediated inhibition of target tissue response to Shh signaling. Science 1998;280:1603-7
   PubMed Web of Science ®Google Scholar
• Tang JY. Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma. Semin Cutan Med Surg 2011;30:S6-9
   PubMedGoogle Scholar
• Kar S, Deb M, Sengupta D, et al. Intrincancies of hedgehog signaling pathways: a perspective in tumorigenesis. Exp Cell Res 2012;318:1959-72
   Google Scholar
• Lin T, Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in d evelopment. Onco Targets Ther 2012;5:47-58
   PubMed Web of Science ®Google Scholar
• Stecca B, Ruiz IAA. Context-dependent regulation of the GLI code in cancer by Hedgehog and non-Hedgehog signals. J Mol Cell Biol 2010;2:84-95
   PubMed Web of Science ®Google Scholar
• Barnfield PC, Zhang X, Thanabalasingham V, et al. Negative regulation of GLI1 and GLI2 activator function by suppressor of fused through multiple mechanisms. Differentiation 2005;73:397-405
   PubMed Web of Science ®Google Scholar
• Liem KF Jr, He M, Ocbina PJ, et al. Mouse Kif7/Costal2 is a cilia-associated protein that regulates sonic hedgehog signaling. Proc Natl Acad Sci USA 2009;106:13377-82
   Web of Science ®Google Scholar
• Wolter M, Reifenberger J, Sommer C, et al. Mutations in the human homologue of the drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997;57:2581-5
   PubMed Web of Science ®Google Scholar
• Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-2
   PubMed Web of Science ®Google Scholar
• Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-10
   PubMed Web of Science ®Google Scholar
• Caro I, Low JA. The role of the Hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res 2010;16:3335-9
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010;16:3113-20
   PubMed Web of Science ®Google Scholar
• Zhao C, Chen A, Jamieson CH, et al. Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-9
   PubMed Web of Science ®Google Scholar
• Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449: a potent inhibitor of Hedgehog pathway. Bioorg Med Chem Lett 2009;19:5576-81
   PubMed Web of Science ®Google Scholar
• LoRusso P, Rudin Ch, Reddy J. Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib(GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res 2011;17:2502-11
   PubMed Web of Science ®Google Scholar
• Von Hoff D, LoRusso P, Rudin Ch, et al. Inhibition of the Hedgehog pathway in advanced basal cell carcinoma. N Engl J Med 2009;361:1164-72
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Dirix AE, et al. Efficcacy and safety of vismodegib in advanced basal cell carcinoma. N Engl J Med 2012;366:2171-9
   PubMed Web of Science ®Google Scholar
• Tang JY, Mackay-Wiggan J, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal cell nevus syndrome. N Engl J Med 2012;366:2180-8
   PubMed Web of Science ®Google Scholar
• Yauch RL, Dijkgraaf GL, Alicke B. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4
   PubMed Web of Science ®Google Scholar
• Dijkgraaf GJ, Alicke B, Weinmann L. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011;71:435-44
   PubMed Web of Science ®Google Scholar
• Buonamici S, Williams J, Morrisey M. Interfering with resistance to Smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl med 2010;2:51ra70
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51
   PubMed Web of Science ®Google Scholar
• Kim J, Tang JY, Gong R, et al. Itraconazole a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 2010;17:388-99
   PubMed Web of Science ®Google Scholar
• Siu L, Papadapoulos K, Alberts S. A first-in-human phase 1 study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 15 - 19 November 2009; Boston, MA, USA
   Google Scholar
• Huff CA, Padmanabhan S, Kelly KR, et al. A phase I study of an oral hedgehog pathway antagonist, BMS-833923, in patients with relapsed or refractory multiple myeloma. Blood 2011;118:3993
   Web of Science ®Google Scholar
• Rudin C, Jimeno A, Miller W. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients with advanced or metastatic solid tumors. J Clin Oncol 2011;29:3014
   Web of Science ®Google Scholar
• Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011;131:1735-44
   PubMed Web of Science ®Google Scholar
• Chang AL, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. JAMA Dermatol 2013;149:639-41
   PubMed Web of Science ®Google Scholar